🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

🚨 New insights in #Takotsubo Syndrome 👉 Great talk by Thomas Stiermaier #DGK2024HT including new data from our translational heart-brain axis by DZHK Germany and our GEIST registry 🎯 Next step randomized treatment studies Elias Rawish Francesco Santoro, MD, PhD Holger Thiele Young DGK

Please read this 🧵. It has a good ending (the author did not have to pay APCs) but as the authors says: "This is not a happy ending, just fair, because this happened only after multiple e-mails I wrote, pointing out the details of the contract, the fact that I wrote them

European Society of Cardiology Journals Philipp Sommer Tee Joo YEO Aaysha Cader Boldizsar Kovacs Erik Rafflenbeul A.Nazmi Calik Obayda Azizy Sara Moscatelli EHJCaseReports Editor-in-Chief Do you really need #Impella to diagnose #Takotsubo ?? I don’t think so #Echofirst #WhyCMR are more than enough Society for Cardiovascular Magnetic Resonance BSEcho

Joined the growing #MedSky wave over at bluesky and it’s like old Twitter in the best possible way 🦋 bsky.app/profile/kateha… Don’t miss this awesome #RadSky starter pack (basically a quick way to find people!) ⬇️ go.bsky.app/Gmkg4yX

Do not overlook comorbidities in #takotsubo syndrome: sciencedirect.com/science/arti... - Higher rates of in-hospital complications + long-term mortality and recurrence in patients with COPD Francesco Santoro, MD, PhD Ingo Eitel IVAN J NUÑEZ GIL Thomas Stiermaier

COPD vs. Heart Failure. Take a look at #ESCHeartFailure: “Phenotyping patients with chronic obstructive pulmonary disease and heart failure.” 👉 bit.ly/3CEmnXX EJHF Editor-in-Chief Jan Biegus @Ppponikowski #HFA_ESC Harriette Van Spall, MD MPH 🇨🇦 Shelley Zieroth Marat Fudim, MD MHS Gregg Fonarow MD Alexandre Mebazaa

First case demonstrating the marked beneficial effects of Aficamten, a cardiac myosin inhibitor, on myocardial energetics, perfusion and oxgenation in HCM after just 12 weeks of treatment. Zakariye Ashkir NIHR Oxford Biomedical Research Centre doi.org/10.1093/ehjci/…

2024 was a blast in cardiovascular imaging congresses led by EACVI. Be ready for #EACVI2025: 📍Vienna 📅11-13 Dcember 👨‍👩‍👦‍👦#EuroeEcho, #EuroCMR and #ICNC-CT together Help us to shape the programme and be part of it 👉escardio.formstack.com/forms/eacvi_20… European Society of Cardiology Camille

#WhyCMR fibro-fatty infiltration, performed after incidental finding during a #yesCCT examination done for CAD exclusion.. the added value of multimodality imaging!

Hot off the press ! The last update on myocardial CT perfusion in clinical practice ! Stay tuned with us ! link.springer.com/article/10.100… #YesCCT #radiology #Cardiology Carlo N. De Cecco, MD, PhD Rodrigo Salgado Luca Saba

La giornalista Cecilia Sala è incarcerata in Iran ilpost.link/LcyiCIjtnP

73 yo man, externally referred for elective coronary angiography because of ECG changes and coronary CT positive for obstructive CAD. Actually: apical hypertrophic cardiomyopathy + small apical aneurysm!!! Always useful to have a second-look at the images from #YesCCT 😉

Cecilia Sala è detenuta in condizioni severe: ilpost.it/2025/01/01/cec….

Le condizioni di Cecilia Sala sono legate a Mohammed Abedini ilpost.it/2025/01/03/cec…

#1 From the SCARE* registry of the M.G. Vannini Hospital - how from a simple #WhyCMR scan follows targeted diagnostic cascade and family screening. * Strange Case REcord

Just published our last research on #takotsubo and Beta-Blocker with the GEIST registry! BBs may help reducing mortality but do not prevent recurrences

Beta-Blockers and Long-Term Mortality in #Takotsubo Syndrome: Results of the Multicenter GEIST Registry | JACC: Heart Failure jacc.org/doi/10.1016/j.…

🌐The SGLT2_HYPE landing page is live! This new trial aims to redefine #hypertension treatment by exploring SGLT2 inhibitors & generate clinical evidence that could reshape guidelines & improve #PatientCare. Visit us at: sglt2-hype.eu/home/ #Hypertension #EU_HaDEA

🗞️📢 First press release from #SGLT2_HYPE just out! . This #HorizonEU clinical trial will explore #SGLT2 inhibitors like #Dapagliflozin as a new standard in #hypertension care 💊💡 Read it here 👉 shorturl.at/yMrGB #ClinicalTrials #EU_HaDEA

🚀👏 The #SGLT2HYPE_GA25 KickOff has begun! Ingo Eitel, Project Coordinator, welcomes all partners unite to study #SGLT2 inhibitors’ proven effective in diabetes & heart failure—as a new therapeutic approach for #hypertension.#Health #CardiovascularHealth #HorizonEU